Edot.com, Inc. Announces New Chief Regulatory Officer.MIAMI Miami, cities, United States Miami (mīăm`ē, –ə). 1 City (1990 pop. 358,548), seat of Dade co., SE Fla., on Biscayne Bay at the mouth of the Miami River; inc. 1896. -- Edot.com, Inc. (Pink Sheets:ECMM ECMM European Community Monitor Mission (now European Union Monitoring Mission; diplomatic mission to Bosnia and Herzegovina starting 1991) ), announced that Krishna Menon joined the Company's scientific advisory board and accepted the position of Chief Regulatory officer. Dr. Menon is a former employee of the year President's award The President's Award may mean:
"I'm very excited at the prospect of joining Nanoviricide," Dr. Menon noted, "this technology represents, in my opinion, a market leading concept. It allows for a textbook finish for so many well conceived APIs, allowing delivery to target cells with lowest dosage, which increases efficacy and reduces toxicity." Dr. Menon returned from a trip to Singapore, where he was a keynote speaker at the drug delivery summit. The Company plans to begin its animal trials this summer on the first of its targeted anti-viral nanoviricides(TM). Dr. Krisna Menon, Chief Regulatory Officer will be supervising and monitoring the animal studies. Dr. Menon is a well known Pharmaceutical Scientist and Executive. He was awarded the Employee of the Year, Presidents Award (1999) at Eli Lilly, where he was a co-inventor of two drugs GEMZAR and ALIMTA which account for nearly one billion dollars in annual sales. Prior to that, he was Senior Research Scientist at Bayer. At present, he is on the board of directors of KARD Scientific, MA, and Biological Supplies, NY, and scientific advisor to Nexus Pharmaceuticals. He is the holder of 7 US patents. Dr. Menon received a PhD from Harvard. While at Harvard, he performed pre-clinical studies on AZT AZT or zidovudine (zīdō`vy  dēn'), drug used to treat patients infected with the human immunodeficiency virus (HIV), which causes AIDS; also called , an important anti-HIV drug. Nanoviricide, Inc. Nanoviricide, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. Nanoviricide, Inc. has exclusive license in perpetuity Of endless duration; not subject to termination. The phrase in perpetuity is often used in the grant of an Easement to a utility company. in perpetuity adj. forever, as in one's right to keep the profits from the land in perpetuity. for technologies developed by Theracour Pharma for the five virus types HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. , HCV HCV abbr. hepatitis C virus HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus. , Herpes, Asian (bird) flu and Influenza. A nanoviricide(TM) is a nanoparticle that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus. When a nanoviricide(TM) drug particle enters the patient's blood stream, it attacks and immobilizes circulating virus particles. Once this is done, the active pharmaceutical ingredient is injected into the virus by the nanoviricide(TM) particle, destroying it. The company plans to develop novel nanoviricide(TM) drugs first against HIV, and anticipates that in 2006/2007, it will license a product or products to major pharmaceutical companies. Forward-Looking Statements Certain statements in this release, and other written or oral statements made by the Company, including the use of the words "expect," "anticipate," "estimate," "project," "forecast," "outlook," "target," "objective," "plan," "goal," "pursue," "on track," and similar expressions, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied. The Company assumes no obligation and does not intend to update these forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: competitive and general economic conditions, adverse effects of litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , the timely development and acceptance of services, significant changes in the competitive environment, the failure to generate or the loss of significant numbers of customers, the loss of senior management, increased government regulation or the company's failure to integrate its acquired companies to achieve the synergies and efficiencies described in the "Management's Discussion and Analysis Management's discussion and analysis (MD&A) A report from management to shareholders that accompanies the firm's financial statements in the annual report. It explains the period's financial results and enables management to discuss topics that may not be apparent in the financial " section of the Company's filings with the Securities and Exchange Commission where applicable, which may be revised or supplemented in subsequent reports on SEC Forms 10-QSB and 8-K. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion